eye problems with glp 1 Possible Link Between GLP-1 RA Medications & Health vision loss glp 1 GLP-1s

Multiple studies have tied changes in the gut microbiome to lower GLP-1 levels, but the mechanism isnt always clearly defined

C., stman, E

The active ingredient in Foundayo, orforglipron, is also being studied as a potential treatment for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, and other conditions

Liraglutide was associated primarily with reduced risk of worsening depression

Beyond Injections: How Oral GLP-1s Will Fit into Obesity Care This edition covers: The newest oral GLP-1s on the market Clinical differences between oral and injectable GLP-1s How a growing range of options is re-shaping health benefit strategies Last week, the FDA approved Lillys new oral GLP-1 medication, Foundayo (orforglipron), several months after the approval of Novo Nordisks Wegovy (semaglutide) pill the first oral GLP1 indicated both for weight management and for reducing cardiovascular risk in adults with obesity or overweight, and established heart disease

Tirzepatide also activates a related GIP receptor, giving it a dual effect that often leads to greater weight reduction